For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

A drug inspired by the anesthetic ketamine just became the first new kind of depression medication in 35 years. Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Janssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a party drug – is to be reviewed by advisers to the FDA at a crunch ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Medicare does not currently provide coverage for ketamine therapy or infusions to treat mental health conditions. This is because the Food and Drug Administration (FDA) only approves the drug ...

March 4, 2025 -- The FDA has approved the first new clot-busting drug in nearly 30 years, offering a faster way to dissolve blood clots in adults who suffer a stroke. The treatment ...